Pharmaceuticals News and Research

RSS

AVEO receives USAN, WHO generic name approval for ficlatuzumab

AVEO Pharmaceuticals, Inc. today announced that the United States Adopted Names (USAN) Council, in consultation with the World Health Organization (WHO) International Nonproprietary Names Expert Committee, has approved the use of the nonproprietary generic name "ficlatuzumab" (pronounced fye" kla tue' zue mab) for AV-299, a potent, functional anti-HGF/c-MET antibody internally discovered at AVEO.

3 Feb 2011

New England Journal publishes fidaxomicin Phase 3 trial results against CDI

Optimer Pharmaceuticals, announced The New England Journal of Medicine has published results from the North American Phase 3 trial evaluating the safety and efficacy of the Company's novel antibiotic fidaxomicin as a treatment for patients with Clostridium difficile infection.

3 Feb 2011

PEARS project reviews professional pharmacy education in Ireland

A research team from Aston University in Birmingham, UK has completed The Pharmacy Education and Accreditation Reviews Project (PEARS), which reviewed professional pharmacy education as a whole in Ireland. The Project was led by Professor Keith Wilson and Dr Chris Langley, who are based in the School of Life & Health Sciences at Aston.

3 Feb 2011

Generic drugs to treat hypertension, heart failure could help NHS save £200 million

Using a generic drug to treat hypertension and heart failure, instead of branded medicines from the same class, could save the UK National Health Service (NHS) at least £200 million in 2011 without any real reduction in clinical benefits.

3 Feb 2011

Fidaxomicin demonstrates 45% reduction in recurrences vs. existing treatment for C. difficile infection

Clostridium difficile infection (CDI) is a significant and growing problem in hospitals and other health care facilities, but no new drugs to treat the condition have been developed in several decades. However, a large-scale, phase 3 trial conducted by Canadian and U.S. researchers shows that the new antibiotic Fidaxomicin is superior to existing treatments, demonstrating a 45 percent reduction in recurrences vs. the existing licensed treatment.

3 Feb 2011

Concert and WRAIR enter CRADA to evaluate novel compound for seizure protection associated with TBI

Concert Pharmaceuticals, Inc. today announced that it has entered into a Cooperative Research and Development Agreement with the Walter Reed Army Institute of Research. The CRADA will allow the WRAIR to conduct preclinical testing on a novel compound derived from Concert's DCE Platform™ (deuterated chemical entity platform) for seizure protection associated with traumatic brain injury, a major public health concern.

3 Feb 2011

HealthCore, AstraZeneca collaborate to conduct real-world studies on disease states, treatment

AstraZeneca Pharmaceuticals LP and HealthCore, the health outcomes research subsidiary of WellPoint, today announced a collaborative agreement to conduct real-world studies designed to determine how to most effectively and economically treat disease.

3 Feb 2011

Angiotech receives letter from TSX to delist its common shares on March 3, 2011

Angiotech Pharmaceuticals, today announced that on February 1, 2011, Angiotech received a letter from the Toronto Stock Exchange stating that Angiotech's common shares will be delisted from the TSX effective at the close of market on March 3, 2011.

3 Feb 2011

FDA disallows obesity drug Contrave pending further large-scale testing

In its latest blow to obesity medication development efforts, the US Food and Drug Administration (FDA) yesterday notified Orexigen Therapeutics that it would need to conduct an extremely large-scale study of the long-term cardiovascular effects of its drug, Contrave, before approval could be considered.

3 Feb 2011

International scientist team identifies gene mutation strongly linked to schizophrenia

In a major advance for schizophrenia research, an international team of scientists, led by Jonathan Sebat, PhD, assistant professor of psychiatry and cellular and molecular medicine at the University of California, San Diego School of Medicine, has identified a gene mutation strongly linked to the brain disorder - and a signaling pathway that may be treatable with existing compounds.

3 Feb 2011

Cedars-Sinai receives California Institute grant to develop new technique for specific diseases

A team of scientists from the Cedars-Sinai Regenerative Medicine Institute has been awarded a $1.9 million grant from the California Institute for Regenerative Medicine to fund development of a new technique to aid pharmaceutical discoveries for specific diseases.

3 Feb 2011

Merz introduces new educational website for patients with focal dystonias

In support of the focal dystonia community, Merz Pharmaceuticals today announced the launch of a new educational website, FocalDystoniaExchange.com, where people affected by certain focal dystonias, as well as caregivers, family and friends, can learn more about the conditions and access helpful resources. For people who suffer from focal dystonias, completing simple, everyday tasks can be a difficult and challenging process.

3 Feb 2011

Isis commences ISIS-FXIRx Phase 1 study for treatment of clotting disorders

Isis Pharmaceuticals, Inc. announced the initiation of a Phase 1 study of ISIS-FXIRx, an antisense drug designed to treat clotting disorders. ISIS-FXIRx inhibits the production of Factor XI, a clotting factor that is an important component of the coagulation pathway. Because of its role in the intrinsic coagulation pathway, inhibition of Factor XI could offer an effective approach for preventing the formation of blood clots with a lower risk of bleeding.

2 Feb 2011

Damaged heart rebuilt with heart stem cells from children with congenital heart disease

A new study, revealing that heart stem cells from children with congenital heart disease were able to rebuild the damaged heart in the laboratory, could provide a new outlet for Emerging Healthcare Solutions' NASA bioreactor.

2 Feb 2011

Shire announces Health Canada's approval of VYVANSE for treatment of ADHD in adolescents and adults

Shire plc, the global specialty biopharmaceutical company, announces that Health Canada has approved VYVANSE® (lisdexamfetamine dimesylate capsules) for the treatment of attention deficit hyperactivity disorder (ADHD) in adolescents and adults.

2 Feb 2011

Inovio publishes scientific paper detailing SynCon DNA vaccine preclinical study for prostate cancer

Inovio Pharmaceuticals, a leader in the development of therapeutic and preventive vaccines against cancers and infectious diseases, announced today the publication of a scientific paper in the journal Human Vaccines detailing potent immune responses in a preclinical study of Inovio's SynCon DNA vaccine for prostate cancer targeting two antigens.

2 Feb 2011

Harbor BioSciences announces publication of newly discovered anti-inflammatory steroids

Harbor BioSciences, a biopharmaceutical company developing novel therapeutics for the treatment of cancer, metabolic and inflammatory diseases, today announced publication of newly discovered anti-inflammatory steroids naturally present in humans.

2 Feb 2011

FDA to inspect Lannett's manufacturing facility for review of Morphine Sulfate NDA

Lannett Company, Inc., a manufacturer of generic pharmaceuticals, today announced that it recently met with the U.S. Food and Drug Administration (FDA) to discuss the status of the company's New Drug Application (NDA) for Morphine Sulfate Oral Solution as well as other pending product applications.

2 Feb 2011

Sanofi-aventis announces GetGoal-X Phase III study of lixisenatide against type 2 diabetes

Zealand Pharma A/S, a biopharmaceutical company dedicated to the discovery and development of innovative peptide drugs, is pleased to announce that its partner, sanofi-aventis, today announced that the GetGoal-X Phase III study of lixisenatide, a once-daily GLP-1 receptor agonist licensed from Zealand Pharma, achieved its primary endpoint of non-inferiority in HbA1c reduction from baseline, compared with exenatide twice-daily.

2 Feb 2011

Skinvisible, Novartis enter agreement for technical feasibility study

Skinvisible Pharmaceuticals, has entered into a feasibility agreement with Novartis Pharma AG. Under the agreement Skinvisible will assess the technical feasibility of a topical formulation with an undisclosed compound utilizing its proprietary Invisicare polymer delivery system.

2 Feb 2011

Pharmaceuticals News and Research

AVEO receives USAN, WHO generic name approval for ficlatuzumab

New England Journal publishes fidaxomicin Phase 3 trial results against CDI

PEARS project reviews professional pharmacy education in Ireland

Generic drugs to treat hypertension, heart failure could help NHS save £200 million

Fidaxomicin demonstrates 45% reduction in recurrences vs. existing treatment for C. difficile infection

Concert and WRAIR enter CRADA to evaluate novel compound for seizure protection associated with TBI

HealthCore, AstraZeneca collaborate to conduct real-world studies on disease states, treatment

Angiotech receives letter from TSX to delist its common shares on March 3, 2011

FDA disallows obesity drug Contrave pending further large-scale testing

International scientist team identifies gene mutation strongly linked to schizophrenia

Cedars-Sinai receives California Institute grant to develop new technique for specific diseases

Merz introduces new educational website for patients with focal dystonias

Isis commences ISIS-FXIRx Phase 1 study for treatment of clotting disorders

Damaged heart rebuilt with heart stem cells from children with congenital heart disease

Shire announces Health Canada's approval of VYVANSE for treatment of ADHD in adolescents and adults

Inovio publishes scientific paper detailing SynCon DNA vaccine preclinical study for prostate cancer

Harbor BioSciences announces publication of newly discovered anti-inflammatory steroids

FDA to inspect Lannett's manufacturing facility for review of Morphine Sulfate NDA

Sanofi-aventis announces GetGoal-X Phase III study of lixisenatide against type 2 diabetes

Skinvisible, Novartis enter agreement for technical feasibility study

Industry Focus - Biopharma eBook

Latest eBooks

A practical guide to lipid nanoparticle formulation and resizing

Editorial Focus eBook - Spatial and single-cell omics (1st edition)

Industry Focus eBook - Analytical Chemistry (3rd edition)

Industry Focus eBook - Microbiome (1st edition)

Improving healthcare sustainability through carbon data

Managing vibration in IVF laboratories

A New Approach to Preventing Bladder Cancer Recurrence